Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Webcast: Navigating new frontiers: Ways to find space in the future RA market

April 9, 2019 | Pharma, Webcast, healthcare, rheumatoid arthritis 

In partnership with pharmaphorum

View the webcast »

The emergence of low-cost biosimilar versions of Humira and the new janus kinase (JAK) inhibitors, are shaking up a once-stable market.

Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely to be the case for much longer, as several other candidates reach late-stage development.

Analysis of Therapy Watch data, a real-time syndicated market tracking tool and Living Withdata, our syndicated patient report series shows that JAK inhibitors have already made a strong impression in the European RA market, where their convenient oral administration advantage may override cost considerations that would otherwise favour biosimilar uptake.

This webcast, held in partnership with pharmaphorum uses the latest intelligence from both physicians and patients to look at emerging trends in the RA market, how these will shape the RA market of tomorrow and how companies can best position themselves for future success.

Topics covered in the webcast include:

  • The European RA market
  • Current status and market situation of JAK inhibitors (key EU5 countries)
  • Uptake curve of JAKS compared to other new entrants and biosimilars
  • The patient profile and unmet needs in RA
  • Profile of physicians prescribing JAKS
  • Country differences
  • The future of new classes of JAK inhibitors

View the webcast »

This content was provided by Inizio

Company Details

- PMLiVE

Inizio

Email
Website

 Latest Content from  Inizio 

Understanding the Patient Journey

The patient journey is changing. Patients are now much more educated and engaged. They have access to information and want to be involved in decisions around their treatment programme.  Technology...

Case Study: Oncology diagnostic biomarker landscaping study

The challenge:Our client needed to understand moleculardiagnostic testing growth opportunities for a new biomarker in oncology. They wanted to understand the current market landscape, identify potential leverage points that would maximise use of the biomarker...

Research Partnership publishes 2016 Living with RA reports

Research Partnership has published new Living with rheumatoid arthritis (RA) EU and US market reports for 2016.

Article: The Art of Storytelling in Pharma Market Research

Published in PBIRG Perspective, May 2016, vol. 18 No.1, By Julie Denny, Marketing Director

Video: Immuno-oncology therapies

Immuno-oncology therapies which harness the body’s own defences to fight off tumours are widely acknowledged as the new frontier in cancer treatment. However, these therapies come with a very high price...

The challenges of conducting effective pharmaceutical market research in emerging markets

Published in Quirk's Marketing Research Review, April 2016, By Marc Yates, Director of Emerging Markets

“Most eye-catching” agency Pegasus scoops the ‘EMEA Healthcare PR Consultancy of the Year’ at Sabre Awards

Pegasus wins the prestigious “EMEA Healthcare PR Consultancy of the Year” award at the recent Sabre Awards in Berlin, organised by The Holmes Report.

Research Partnership appoints Director and Head of Business Analytics, North America

Tom has been appointed a Director in our Philadelphia office. He has over 25 years’ experience in healthcare research and has an extensive background in both quantitative and qualitative research,...

Article: The Art of Storytelling in Pharma Market Research

Published in PBIRG Perspective, May 2016, vol. 18 No.1, By Julie Denny, Marketing Director

Event: EphMRA Annual Conference 2016

Frankfurt, Germany 21 - 23 June 2016